AnHorn Medicines is a novel drug discovery platform company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Our mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.

LumiSTAR Biotechnology focuses on development of various drug screening platforms for pharmaceutical and CRO companies. We have been committed to accelerate drug development process. Our core technologies are various optical genetically-encoded reporters (with different detection dynamic ranges), which can be incorporated with iPSC or disease-model cell lines for real-time monitoring how the cellular physiology influenced by testing drugs. LumiSTAR’s drug screening platform can apply on phenotypic screening, drug discovery, toxicity testing, and precision/personalized medicine.

ARVIN Bio-Medical Devices Co., Ltd. is located next to Hsinchu Science Park, Taiwan. Our company's current main business and development are as follows:

1. Combined with medical technology, and developed a personal portable product.
2. Provide customized detection circuit module service.
3. Develop various detectors and combine mobile APP modules.
4. Develop 3D image scanner software/hardware.
5. Develop innovative medical materials in conjunction with clinicians and academia.
6. Medical equipment related consulting services.

Energy Resources International Co., Ltd. (ERI), a pioneer in X-ray radiography, has stepped into medical equipment field and has dedicated to its effort to explore and master the properties and application of Carbon Nanotube (CNT) technology since 2013. The first area of focus has been in the development of world’s first CNT-driven Cold Cathode as the X-ray emission source. ERI has applied this technological breakthrough first to the development of the battery-powered handheld X-ray devices. These handheld devices not only drastically change the experience of the dental patients but also lower the operating costs of the dentist offices. From the handheld devices, ERI proceeds to explore opportunities in the portable general purpose X-ray systems for extremities with the vision to continuously improve the timeliness, convenience, and effectiveness of the X-ray experiences. In addition to using and improving X-ray as a diagnostic tool, ERI has been exploring opportunities on the treatment side of the healthcare needs. The most recent conversation on the treatment side surrounds the ground-breaking Intraoperative Radiotherapy (IORT) for breast and skin cancer therapy.

Advanced biomedical technology (ABT) is a startup who focusing on 3D printing biodegradable implant. ABT was founded in Taiwan and have GMP facility for medical grade 3D printing service. ABT provide the service with high quality and high-performance medical grade biomaterials, biodegradable implant and 3D printing total solution.

Applato, app+plate, designs proactive dietary solutions with "food image recognition technology" and "dietary recommendation algorithm" to assist healthcare or food-related facilities in developing customized health management and meal recommendation service.  This is developed by an integrated team of AI engineers, UI/UX designer, marketing advisor, and more than 10 cooperative specialist dietitians.  Our goal is to provide tasty, healthy, and convenient food for better wellness.

Designed and Developed in Taiwan
In 2018, Brain Navi Biotechnology developed NaoTrac, the first Autonomous surgical navigation robot with machine vision specially designed for cranial neurosurgery. Until current research, it is enough to fit in the routine clinical setting. Brain Navi Biotechnology is mainly focusing on developing and researching innovative neurosurgical navigation system.

With the outstanding doctors, researchers, and developers in Taiwan to combine technical and clinical application experience, developing products driven by demand. Takes Taiwan’s advantages in R&D and production in the electronics industry, selecting Taiwan as a research and development and production base. Brain Navi will focus on the global market and create sustainable value management.

https://www.taiwanglobalization.net/portfolio/the-future-of-brain-surgery-comes-from-brain-navi

BROADSIMS believes that medical devices should be suitable for better solution with accuracy and acceleration. We aim to establish a smart industrial ecology of medical equipment and establish a standard inspection platform that complies with medical regulations. Based on such a concept, we created AI-Based Verification System, AVS®.

LinkedIn: Bruce Yu http://www.linkedin.com/in/bruceyu-broadsims

WHAT IS GENE EDITING?
This technology is like Microsoft “Word”, which allows scientists to freely edit genes – inserting, deleting, revising and replacing DNA in plants, animals and even humans. It is a revolutionary invention.
LARGE SEGMENT GENE EDITING TECHNOLOGY
(LS-CRISPR)
LS-CRISPR can simultaneously manipulate 3-10 times size of a target gene comparing with the existing gene editing technology. With LS-CRISPR, we can speed-up R&D processes and precisely produce macromolecular proteins, overcoming the hurdle of mass production of large-size proteins.
GENE EDITING APPLICATION
Gene editing can be applied to many fields such as clinical and basic medicine - drug screen model, hypertension mouse model and immune cell therapy. Gene editing can also bring new options to agriculture - anti-viral pigs, no-turning-brown mushrooms and environmental protection. Many applications and products derived from gene editing tech are now at different stage toward market.

i-Navi Biomedical Inc., founded by Prof. Ching Shiow Tseng and his team members with more than 20-years’ experience in surgical navigation system development, is a company specialized in developing image-assisted/robotic surgical navigation systems for neurosurgery and orthopedic surgery. The 2D/3D C-arm or CT/CTA/MRI images based i-Navi robotic surgical navigation system (robot is an option) for spine/brain surgery enables surgeons to accurately and efficiently position surgical instruments and implants during operations. Using the i-Navi navigation system in minimally invasive spine/brain surgery can significantly reduce X-ray radiation exposure, improve positioning accuracy and surgical risk, and even reduce operation time. Clinical applications of the input image assisted navigation system have been tested and validated at Cathy General Hospital and Tao-Yuan General Hospital. Filing applications for FDA/TFDA approval will be done in one year. The company's goal aims to develop advanced robotic surgical systems to assist medical treatments and improve patients' health. Integration of new technologies such as AI, AR/MR into i-Navi systems to enhance system functions and capabilities is in progress.

iMedtac focusing on building the next generation of integrated care platform with the newest technology of the Internet of Medical Things (IoMT). So the doctors, nurses and patients can use cloud service platform to provide the best quality of comprehensive care and instant multi-party communication.

Milestone :
2016 : Company established.
2016 : Build Asia's first fully intelligent hospital “Yuanlin Christian Hospital”.
2018 : Won Innoaward Taiwan-healthcare Award.
2019 : ADC (Automated-Dispensing Cabinet) Won 16th National Innovation Award.

www.imedtac.com

What We Bring to You?
MedicusTek® is designed and built for People in healthcare environment.
We help to reduce bed falls and pressure injuries with a data-driven and contact-free approach. The Predictive Patient Monitoring actively monitors patients in bed and alerts caregivers BEFORE potential bed exits and when repositioning is required.

Dynamic Otological Data For Next Generation's Health.
We are Devoted to innovating for Improved Life and Patient Care.

RAPID-Health Program is the soft-landing bridge to help the healthcare startups and scale-ups to connect to the healthcare ecosystem in Europe, via Utrecht Region.

Singular Wings Medical Co., Ltd. focus on health care and medical device including hardware design, software development and clouds platform services. Our products and services can be widely applied on resident care, disease care, health management, fitness, competitions, training, sports and other applications. We develop wearable devices which detect physiological signal and combine with smart watches, smart clothing, palm-type measurement device, etc.

Soteria Biotech Co., Ltd. is a Taiwan-based company that develops innovative medical software. It develops patents and sells products for respiratory diseases. Our first product “Soteria One Point Zero” is a medical cloud software designed to assist in the diagnosis and treatment of Obstructive Sleep Apnea Syndrome (OSAS). The development of this product originated from the CEO Honda Hsiao’s ten-year research in the sleep medicine field at the National Center for High-performance Computing. During the research period, he worked together with the Sleep Center of Chang Gung Memorial Hospital and the Sleep Center of China Medical University and successfully published results. Established Soteria Biotech Co., Ltd., and actively developed more advanced and better products. Currently, it has obtained patients in Taiwan, the United States and Singapore. The main target customers are patients with OSAS and patients waiting in line for diagnosis, to provide better solutions.

Taiwan RedEye Biomedical Inc. is a start-up company from Hsinchu, Taiwan. RedEye contributes to doing the research and development on device which can detect if there is any trace of blood hidden in the excrement. Our goal is to help people find the initial symptoms of colorectal cancer, kidney disease, and bladder cancer and to be aware of the situation of inflammation throughout the body in order to realize home health monitoring. Doing well on daily health management can achieve the goal of early detection and early treatment. RedEye’s R&D center is in Taiwan. Our manufacturing base is in Taiwan and China, and we view the whole world as our stages and markets.

Targetrust Biotech is founded in 2016. Our team includes doctors of Changhua Christian Hospital, and professor of Taipei Medical University.
Dr. Ming-Chung Jiang is the company's founder and primary inventor of the company's core scientific technology. Based on the world's first invention “Tumor Signal - Liquid Biopsy” method (assay tumor signal transduction activity in blood), the company is developing and preparing to commercialize innovative the diagnostic products (DxSure cancer therapy resistance detection reagent) for early, real-time, sensitive, and cost-saving monitoring the therapy resistance of all cancer types and all therapy methods.
Products: 1. Reagent for monitoring cancer therapy resistance in real-time, 2. Targeted Antibody-drug conjugates (ADC) for extensive cancer treatments, 3. Targeted contrast agent for imaging-guided surgery for extensive cancer surgery, 4. Targeted magnetic hyperthermia for extensive cancer treatment

Vibrasee is a micro-vibration detector. By using optic method, it can “see” the vibration on skin causing by heartbeat, blood vessel pumping, nerves reflection, and muscle stretching, and then recognize the shacking pattern via deep learning. Since the vibration pattern keeps similar both in early and late stage, Vibrasee can detect many diseases in very early phase. On the other hand, the light source applying in Vibrasee is visible light, which is no-radiation and non-invasive. Thus, it can be applied in daily detection. We are still teaching Vibrasee to recognize disease pattern. Our first targeted disease is Parkinson’s disease.

Taiwan-based Instant NanoBiosensors (INB) is a pioneer that specializes in light-sensing biosensor platform development. The mission of the company’s dynamic and problem-driven R&D team is to advance biomedical research and improve patient care by providing customers with simple, reliable, and cost-effective solutions. Its state-of-the-art fiberoptic particle plasmon resonance (FOPPR) technology offers instant and accurate results for a wide range of detection applications. By combining novel biomarkers with a cutting-edge biosensing platform, INB aspires to revolutionize traditional immunoassays and analyses for a more efficient healthcare ecosystem.

Immunotherapy is the only breakthrough therapy in cancer treatment in recent years. One main requirement for successful cancer immunotherapy is to generate effective anti-tumor T-cell populations.

ManysmarT Therapeutics aims to deliver highly effective anti-tumor T-cell therapeutics by:

supplying abundant and high purity γ9δ2 T cells at an effector memory cell stage;
combining our ADCC (Antibody-Dependent Cell-mediated Cytotoxicity)-enhancing BiTE (Bispecific T cell Engager) to promote stronger interaction between therapeutic antibodies and the supplied/endogenous T cells and thus, result in a higher ADCC effect than that from using therapeutic antibodies alone;
combining γ9δ2 T cells with our own or commercial BiTEs to synergistically enhance their therapeutic effects;
enabling an easy switch to another therapeutic antibodies/targets to overcome the antigen loss issue commonly observed in advanced cancer;
generating neoantigen-specific T Cell Receptor (TCR)-redirected γ9δ2 T cells for cancer/infectious diseases treatment.

We apply microfluidics as our core technique to develop an in vitro diagnostic (IVD) system to support the precision medicine of antibiotics. Targeting the emergence of antimicrobial resistance (AMR) which is literally one of the ten threats to the global health in 2019 according to WHO. Our system, fAST, can carry out rapid bacteria identification within 1.5 hours, following by a multiple antibiotics combination test within 5 hours. To conclude, we are the fastest and first-in-class system in the market that can optimize three different kind of antibiotics combination to provide clinicians with accurate and personalized results.